Published on 8 Jun 2016
Satu
Vainikka, chief executive of ValiRx Plc (LON:VAL), tells Proactive
Investors the company is discussions with larger companies over
potential licencing deals and collaborations for its lead cancer drug
VAL 201.
The company is to broaden the phase I/II clinical trial of its lead cancer drug to speed up the dose expansion stage, allowing it to complete the prostate cancer trial within the projected and regulatory-agreed time frame.
“A biotech business model is to take things from A to B and once you start reaching B, which in our case is Phase II clinical trials, we are starting to talk to big pharmaceutical companies or bigger biotech companies,” Vainikka says.
The company has also started preparatory work on a full efficacy study (phase III) of the drug in prostate cancer treatment.
www.valirx.com/
www.proactiveinvestors.com/LON:VAL/ValiRx
http://www.4-traders.com/VALIRX-PLC-22619385/
Beaufort's pleased to announce we've been appointed corporate broker for ValiRx https://t.co/IuGilZrKtj #VAL #ValiRx pic.twitter.com/hzOFxXLjm9
— Beaufort Securities (@BeaufortSec) June 7, 2016
#ValiRx #joint #venture awarded second US #patent... https://t.co/OmJROLEQw6 pic.twitter.com/oprgPJZWjB
— agencyIP (@AgencyIP) May 7, 2016
@BlueShareForum Quarterly update on clinical developments for #Valirx - listen at https://t.co/F6o9VhBZOy $val #biotechnology
— BRR Media UK (@brr_mediauk) June 8, 2016
No comments:
Post a Comment